PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
153.33%
Revenue growth above 1.5x AXSM's 44.67%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
73.30%
Gross profit growth above 1.5x AXSM's 47.97%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-15.23%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.23%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-9.33%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.41%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-8.33%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.98%
Share count expansion well above AXSM's 4.18%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.03%
Diluted share reduction more than 1.5x AXSM's 4.18%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-36.10%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-34.66%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.84%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
71.82%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
66.77%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
96.67%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
77.76%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
53.48%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
61.16%
Below 50% of AXSM's 1101.37%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-44.17%
Negative 5Y equity/share growth while AXSM is at 179.78%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
152.11%
3Y equity/share CAGR similar to AXSM's 149.83%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AXSM invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.40%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.77%
We’re deleveraging while AXSM stands at 0.37%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
8.30%
We increase R&D while AXSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
28.80%
SG&A growth well above AXSM's 50.39%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.